Diagnos (ADK) Trading Down 12.5%

Share on StockTwits

Diagnos Inc (CVE:ADK)’s share price fell 12.5% during trading on Wednesday . The stock traded as low as C$0.04 and last traded at C$0.04. 295,000 shares were traded during mid-day trading, a decline of 65% from the average session volume of 850,167 shares. The stock had previously closed at C$0.04.

The stock has a market capitalization of $8.52 million and a PE ratio of -1.74.

Diagnos (CVE:ADK) last issued its quarterly earnings data on Wednesday, February 27th. The company reported C($0.01) earnings per share for the quarter. The company had revenue of C$0.10 million during the quarter.

TRADEMARK VIOLATION NOTICE: “Diagnos (ADK) Trading Down 12.5%” was reported by Zolmax and is the sole property of of Zolmax. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://zolmax.com/investing/diagnos-adk-trading-down-12-5/3041983.html.

Diagnos Company Profile (CVE:ADK)

DIAGNOS Inc provides software-based interpretation services primarily in Canada, the United Arab Emirates, Saudi Arabia, Slovakia, and the United States. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy.

See Also: What is a Reverse Stock Split?

Receive News & Ratings for Diagnos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diagnos and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Seaport Global Securities Equities Analysts Reduce Earnings Estimates for National-Oilwell Varco, Inc.
Seaport Global Securities Equities Analysts Reduce Earnings Estimates for National-Oilwell Varco, Inc.
Financial Analysis: KLX Energy Services  and C&J Energy Services
Financial Analysis: KLX Energy Services and C&J Energy Services
Head to Head Contrast: Valeritas  vs. Luminex
Head to Head Contrast: Valeritas vs. Luminex
Pareteum Corp  Receives Consensus Recommendation of “Buy” from Analysts
Pareteum Corp Receives Consensus Recommendation of “Buy” from Analysts
Zacks: Brokerages Expect ConforMIS Inc  Will Announce Earnings of -$0.12 Per Share
Zacks: Brokerages Expect ConforMIS Inc Will Announce Earnings of -$0.12 Per Share
CSFB Reiterates “C$8.00” Price Target for Centerra Gold
CSFB Reiterates “C$8.00” Price Target for Centerra Gold


 
© 2006-2019 Zolmax.